Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 6.6% in August

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 25,800 shares, an increase of 6.6% from the August 15th total of 24,200 shares. Based on an average daily trading volume, of 56,000 shares, the short-interest ratio is presently 0.5 days.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ:GNOM opened at $11.35 on Thursday. The firm has a market cap of $84.44 million, a price-to-earnings ratio of -4.87 and a beta of 1.03. The firm has a fifty day moving average price of $11.27 and a 200 day moving average price of $10.89. Global X Genomics & Biotechnology ETF has a fifty-two week low of $8.63 and a fifty-two week high of $12.53.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Centaurus Financial Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 14.6% in the fourth quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock worth $147,000 after buying an additional 1,624 shares in the last quarter. Insight Advisors LLC PA purchased a new position in shares of Global X Genomics & Biotechnology ETF in the first quarter valued at $152,000. James J. Burns & Company LLC bought a new stake in Global X Genomics & Biotechnology ETF in the second quarter worth $181,000. Archford Capital Strategies LLC raised its stake in Global X Genomics & Biotechnology ETF by 59.1% during the second quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock valued at $385,000 after purchasing an additional 13,703 shares in the last quarter. Finally, McGuire Investment Group LLC raised its stake in Global X Genomics & Biotechnology ETF by 6.7% during the first quarter. McGuire Investment Group LLC now owns 58,651 shares of the company’s stock valued at $667,000 after purchasing an additional 3,696 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.